Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with ...
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown ...
Anixa Biosciences, Inc. ("Anixa" or the "Company") , a biotechnology company focused on the treatment and prevention of ...
Objectives Patients with primary Sjögren’s disease (SjD) have an increased risk of B cell lymphoma. The aim of this study was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback